TY - JOUR
T1 - Nanoparticles for Stem Cell Therapy Bioengineering in Glioma
AU - Ruiz-Garcia, Henry
AU - Alvarado-Estrada, Keila
AU - Krishnan, Sunil
AU - Quinones-Hinojosa, Alfredo
AU - Trifiletti, Daniel M.
N1 - Funding Information:
This publication was made possible through the support of the Eveleigh Family Career Development Award for Cancer Research at Mayo Clinic in Florida. AQ-H was supported by the Mayo Clinic Professorship, the Mayo Clinic Clinician Investigator award, the Florida Department of Health Cancer Research Chair Fund, and the NIH (R43CA221490, R01CA200399, R01CA195503, and R01CA216855).
Publisher Copyright:
© Copyright © 2020 Ruiz-Garcia, Alvarado-Estrada, Krishnan, Quinones-Hinojosa and Trifiletti.
PY - 2020/12/7
Y1 - 2020/12/7
N2 - Gliomas are a dismal disease associated with poor survival and high morbidity. Current standard treatments have reached a therapeutic plateau even after combining maximal safe resection, radiation, and chemotherapy. In this setting, stem cells (SCs) have risen as a promising therapeutic armamentarium, given their intrinsic tumor homing as well as their natural or bioengineered antitumor properties. The interplay between stem cells and other therapeutic approaches such as nanoparticles holds the potential to synergize the advantages from the combined therapeutic strategies. Nanoparticles represent a broad spectrum of synthetic and natural biomaterials that have been proven effective in expanding diagnostic and therapeutic efforts, either used alone or in combination with immune, genetic, or cellular therapies. Stem cells have been bioengineered using these biomaterials to enhance their natural properties as well as to act as their vehicle when anticancer nanoparticles need to be delivered into the tumor microenvironment in a very precise manner. Here, we describe the recent developments of this new paradigm in the treatment of malignant gliomas.
AB - Gliomas are a dismal disease associated with poor survival and high morbidity. Current standard treatments have reached a therapeutic plateau even after combining maximal safe resection, radiation, and chemotherapy. In this setting, stem cells (SCs) have risen as a promising therapeutic armamentarium, given their intrinsic tumor homing as well as their natural or bioengineered antitumor properties. The interplay between stem cells and other therapeutic approaches such as nanoparticles holds the potential to synergize the advantages from the combined therapeutic strategies. Nanoparticles represent a broad spectrum of synthetic and natural biomaterials that have been proven effective in expanding diagnostic and therapeutic efforts, either used alone or in combination with immune, genetic, or cellular therapies. Stem cells have been bioengineered using these biomaterials to enhance their natural properties as well as to act as their vehicle when anticancer nanoparticles need to be delivered into the tumor microenvironment in a very precise manner. Here, we describe the recent developments of this new paradigm in the treatment of malignant gliomas.
KW - bioengineering
KW - biomaterials
KW - glioma
KW - nanoparticles
KW - nanotechnology
KW - stem cells
KW - surface functionalization
KW - targeting
UR - http://www.scopus.com/inward/record.url?scp=85098066443&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098066443&partnerID=8YFLogxK
U2 - 10.3389/fbioe.2020.558375
DO - 10.3389/fbioe.2020.558375
M3 - Review article
AN - SCOPUS:85098066443
SN - 2296-4185
VL - 8
JO - Frontiers in Bioengineering and Biotechnology
JF - Frontiers in Bioengineering and Biotechnology
M1 - 558375
ER -